# Mounjaro Clinical Trials Overview

## SURMOUNT Program (Weight Management)

The SURMOUNT clinical trial program evaluates tirzepatide for weight management in adults with obesity or overweight.

---

### SURMOUNT-1
**Focus:** Obesity/overweight without diabetes

| Parameter | Details |
|-----------|---------|
| Trial Type | Phase 3, double-blind, randomized, controlled |
| Participants | 2,539 adults |
| Duration | 72 weeks (includes 20-week dose escalation) |
| Published | NEJM, 2022 |
| ClinicalTrials.gov | NCT04184622 |

**Results:**
- 5 mg: -15.0% body weight
- 10 mg: -19.5% body weight  
- 15 mg: -20.9% body weight
- Placebo: -3.1% body weight

**Key Finding:** 50-57% of participants on higher doses achieved ≥20% weight reduction

---

### SURMOUNT-2
**Focus:** Obesity + Type 2 Diabetes

| Parameter | Details |
|-----------|---------|
| Trial Type | Phase 3 |
| Duration | 72 weeks |
| Published | NEJM, 2023 |

**Results:**
- Up to **15.7%** body weight loss
- Superior to placebo in participants with obesity/overweight AND T2D

---

### SURMOUNT-4
**Focus:** Weight maintenance after initial loss

| Parameter | Details |
|-----------|---------|
| Design | Open-label (36 weeks) → Double-blind (52 weeks) |

**Results:**
- Initial phase: 20.9% mean weight reduction
- Continued tirzepatide: Additional 5.5% reduction
- Switched to placebo: 14% weight regain

**Key Finding:** Continued treatment necessary to maintain weight loss

---

### SURMOUNT-OSA
**Focus:** Obstructive Sleep Apnea + Obesity

| Parameter | Details |
|-----------|---------|
| Trial Type | Two Phase 3 trials |
| Population | Adults with moderate-to-severe OSA and obesity |

---

## SURPASS Program (Type 2 Diabetes)

The SURPASS clinical trial program evaluates tirzepatide for glycemic control in adults with type 2 diabetes.

---

### SURPASS-1 through SURPASS-5
**Focus:** T2D glycemic control vs placebo and active comparators

**Comparators tested:**
- Placebo
- Semaglutide (SURPASS-2)
- Insulin degludec
- Insulin glargine

**Results:**
- Statistically significant reductions in HbA1c
- Significant body weight reduction
- Effects sustained up to 104 weeks
- In SURPASS-2: Tirzepatide outperformed semaglutide in A1C reduction

---

### SURPASS-CVOT
**Focus:** Cardiovascular Outcomes

| Parameter | Details |
|-----------|---------|
| Trial Type | Phase 3 cardiovascular outcomes trial |
| Comparator | Trulicity (dulaglutide) |
| Full results | Expected September 2025 |

**Topline Results:**
- Met primary objective (non-inferior MACE-3 vs Trulicity)
- **8% lower risk** of MACE-3 events vs Trulicity
- **16% lower rate** of all-cause death vs Trulicity
- Improvements in A1C, weight, and renal function

---

### SURPASS-PEDS
**Focus:** Pediatric population (ages 10-17)

| Parameter | Details |
|-----------|---------|
| Population | Children/adolescents with T2D |
| Duration | 30 weeks |
| Published | The Lancet |

**Results:**
- Met primary and key secondary endpoints
- Superior improvements in A1C vs placebo
- Superior improvements in BMI vs placebo

---

## Key Publications

| Trial | Journal | Year |
|-------|---------|------|
| SURMOUNT-1 | NEJM | 2022 |
| SURMOUNT-2 | NEJM | 2023 |
| SURMOUNT-4 | NEJM | 2024 |
| SURPASS-PEDS | The Lancet | 2024 |

---

## Download Links for Full Publications

- **SURMOUNT-1:** https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- **SURMOUNT-2:** https://www.nejm.org/doi/full/10.1056/NEJMoa2303162
- **PubMed Abstract:** https://pubmed.ncbi.nlm.nih.gov/35658024/
- **ClinicalTrials.gov:** https://clinicaltrials.gov/study/NCT04184622
